Abstract
In this issue of Blood, Su et al employ an elegant microRNA (miRNA or miR) conjugation strategy to unleash the potential of targeted miRNA therapeutics, and, as a proof of concept, effectively counteract common inflammatory and myeloid disease states.
MeSH terms
-
Humans
-
Inflammation
-
Leukemia*
-
MicroRNAs*
-
Myeloid Progenitor Cells
-
NF-kappa B